MAPT and Alzheimer disease: In the sCJD cohort, both plasma and CSF GFAP variably correlated with plasma and CSF neurodegeneration biomarkers, likely reflecting the close relationship between neuroinflammation and neurodegeneration, as previously described [16,17], but not with AD core biomarkers (p-tau and the Aβ42/Aβ40 ratio).